SA520420308B1 - مشتقة أكسوبيريدين تحمل بدائل - Google Patents

مشتقة أكسوبيريدين تحمل بدائل

Info

Publication number
SA520420308B1
SA520420308B1 SA520420308A SA520420308A SA520420308B1 SA 520420308 B1 SA520420308 B1 SA 520420308B1 SA 520420308 A SA520420308 A SA 520420308A SA 520420308 A SA520420308 A SA 520420308A SA 520420308 B1 SA520420308 B1 SA 520420308B1
Authority
SA
Saudi Arabia
Prior art keywords
prophylaxis
diseases
amino
disorders
preparation
Prior art date
Application number
SA520420308A
Other languages
English (en)
Inventor
هيرستيجن أدريان
لوبيل ماريو
شيروك هارتموت
Original Assignee
باير فارما أكتينغزِلشافت
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by باير فارما أكتينغزِلشافت filed Critical باير فارما أكتينغزِلشافت
Publication of SA520420308B1 publication Critical patent/SA520420308B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بمركب 5-({6-أمينو-2-[4-(5-كلورو-2-سيانو فنيل)-5-مثوكسي-2-أكسوبيريدين-1(2H)-يل]-3-مثيل هكسانويل}-أمينو) بيرازولو[1، 5-أ] بيريدين-3-كربوكساميد 5-({6-amino-2-[4-(5-chloro-2-cyanophenyl)-5-methoxy-2-oxopyridin-1(2H)-yl]-3-methylhexanoyl}amino)pyrazolo[1,5-a]pyridine-3-carboxamide، وبعمليات لتحضيره، باستخدامه لمعالجة و/أو الوقاية من الأمراض واستخدامه لتحضير أدوية لمعالجة و/أو الوقاية من الامراض، بالتحديد اضطرابات قلبية وعائية cardiovascular disorders، وعلى نحو مفضل اضطرابات تخثرية أو تخثرية انسدادية thrombotic or thromboembolic disorders، ووذمات edemas، وأيضا اضطرابات متعلقة بالعين ophthalmic disorders، واستخدامها لتثبيط نشاط بلازما الكاليكريين plasma kallikrein المزعج للقيام بالإجراءات خارج الجسم والفحوصات التحليلية.
SA520420308A 2018-04-10 2020-10-08 مشتقة أكسوبيريدين تحمل بدائل SA520420308B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18166490 2018-04-10

Publications (1)

Publication Number Publication Date
SA520420308B1 true SA520420308B1 (ar) 2022-09-29

Family

ID=61965754

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520420308A SA520420308B1 (ar) 2018-04-10 2020-10-08 مشتقة أكسوبيريدين تحمل بدائل

Country Status (16)

Country Link
US (1) US11884660B2 (ar)
EP (1) EP3774796B1 (ar)
JP (1) JP7333336B2 (ar)
KR (1) KR20200141445A (ar)
CN (1) CN111902414B (ar)
AU (1) AU2019251699B2 (ar)
BR (1) BR112020018237A2 (ar)
CA (1) CA3096480A1 (ar)
DK (1) DK3774796T3 (ar)
ES (1) ES2922533T3 (ar)
IL (1) IL277811B2 (ar)
MX (1) MX2020010635A (ar)
PE (1) PE20210165A1 (ar)
SA (1) SA520420308B1 (ar)
SG (1) SG11202008352YA (ar)
WO (1) WO2019197244A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116874469B (zh) * 2023-09-06 2023-11-10 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途
CN116947818B (zh) * 2023-09-18 2023-12-19 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物、中间体及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
US9475809B2 (en) 2013-07-23 2016-10-25 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
US9765070B2 (en) 2013-10-30 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
WO2016046164A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
WO2016046166A1 (de) 2014-09-24 2016-03-31 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
ES2694189T3 (es) 2014-09-24 2018-12-18 Bayer Pharma Aktiengesellschaft Derivados de oxopiridina sustituidos
EP3197896B1 (de) * 2014-09-24 2019-01-30 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
EP3197880B1 (de) 2014-09-24 2018-10-24 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
EP3271332A1 (de) 2015-03-19 2018-01-24 Bayer Pharma Aktiengesellschaft Oxopyridin-derivate als faktor xia hemmer zur behandlung von thrombose
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
WO2017037051A1 (de) 2015-09-04 2017-03-09 Bayer Pharma Aktiengesellschaft Substituierte oxopyridin-derivate
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
PE20210165A1 (es) 2021-01-26
ES2922533T3 (es) 2022-09-16
JP7333336B2 (ja) 2023-08-24
KR20200141445A (ko) 2020-12-18
AU2019251699A1 (en) 2020-09-24
SG11202008352YA (en) 2020-09-29
JP2021521132A (ja) 2021-08-26
EP3774796A1 (en) 2021-02-17
US20210147414A1 (en) 2021-05-20
MX2020010635A (es) 2020-10-28
AU2019251699B2 (en) 2024-02-29
IL277811B1 (en) 2023-08-01
EP3774796B1 (en) 2022-04-27
CN111902414B (zh) 2023-08-04
US11884660B2 (en) 2024-01-30
WO2019197244A1 (en) 2019-10-17
DK3774796T3 (da) 2022-07-18
BR112020018237A2 (pt) 2020-12-29
IL277811B2 (en) 2023-12-01
IL277811A (en) 2020-11-30
CA3096480A1 (en) 2019-10-17
CN111902414A (zh) 2020-11-06

Similar Documents

Publication Publication Date Title
PH12020551973A1 (en) Substituted dihydropyrazolo pyrazine carboxamide derivatives
ZA202303227B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
MA42376B1 (fr) Dérivés d'oxopyridine substitués
EP4249076A3 (en) (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-2-methoxy-n-(pyridin-2-yl)benzamide as btk-inhibitor
SA520420308B1 (ar) مشتقة أكسوبيريدين تحمل بدائل
MX2023010750A (es) Nuevos usos de derivados de piperidinil-indol.
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
NO20082044L (no) Kombinasjonsterapi innbefattende substituerte oksazolidinoner for prevensjon og behandling av cerebrale kretslopssykdommer
MX2017012430A (es) Formas solvatadas de un inhibidor de tirosina quinasa de bruton.
JO2798B1 (ar) ( أوكسازوليدينون-5-يل-ميثيل) -2-ثيوفين-كاربوكسميدات مُستبدلة وإستخدامها في مجال تخثر الدم
PH12017500977A1 (en) 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
HK1093729A1 (en) Substituted quinolones
MX2017009600A (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero.
TN2018000376A1 (en) Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine-3(2h)-ones and 2,5,6,7-tetrahydro-3h-pyrrolo[2,1-c][1,2,4]triazol-3-ones, and use thereof.
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
PH12019502462A1 (en) Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
WO2018080146A3 (ko) 단백질 탈 인산화 효소 1 억제 펩타이드를 포함하는 혈관 질환 치료용 조성물
HK1144574A1 (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
TW200635920A (en) Pyrazinedicarboxamides and their use